2mg Wegovy: Understanding This Dose Step in the Semaglutide Schedule

What the licensed trial data show about semaglutide's dose steps

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity over 68 weeks. Participants on semaglutide 2.4mg achieved an average body-weight reduction of around 15%, a result that formed the clinical basis for Wegovy's licence. The trial used the full escalation sequence ending at 2.4mg; no arm tested a 2mg maintenance dose, because 2mg is not part of the licensed schedule. It never has been. The approved steps exist because each one was tested for tolerability and efficacy before regulators accepted the data. Changing the dose outside that sequence, including sitting at an unlicensed 2mg indefinitely, means leaving the evidence base entirely.

A question our prescribers hear most weeks is whether staying at a lower dose for longer produces steadier results with fewer side effects. The honest answer is: the trials were not designed to test that hypothesis, so we cannot say. What the data do support is that the step-by-step schedule, as licensed, reduces the severity and frequency of gastrointestinal side effects by giving the body time to adjust before each increase. The NHS semaglutide medicines page sets out the approved schedule clearly.

Where the "2mg Wegovy" label actually comes from

The most common source is unlicensed compounded semaglutide, often sold as vials or cartridges for self-mixing, at doses specified by the seller rather than by a licensed manufacturer. If you are using a compounded vial, our guide on how to mix semaglutide 2mg explains the process, though it is important to understand that compounded semaglutide is not the same product as Wegovy. It has not undergone the same manufacturing quality standards, stability testing, or clinical review. The MHRA has issued repeated public warnings about fake and unlicensed weight-loss injectables; products sold without a prescription from an unverified source carry real risks, including incorrect concentration, contamination, and inaccurate dosing. You can read more about what genuine Wegovy involves on the Wegovy overview page and check any online pharmacy against the GPhC register at pharmacyregulation.org.

It is also worth noting that "2mg" sometimes appears as a transcription error or informal rounding of the 1.7mg or 2.4mg steps, particularly in online forums where people discuss their titration. If you have been prescribed what someone else is calling 2mg, check your prescription and patient information leaflet carefully, and speak to your prescriber if anything is unclear. For a broader look at the evidence around semaglutide as a medicine, the semaglutide information page covers the licensed landscape in full.

The 1.7mg step: what actually happens at this stage in the schedule

The 1.7mg dose is the closest licensed step to "2mg" and is where most people on Wegovy spend around four weeks before reaching maintenance. At this point the appetite-suppressing effect of semaglutide is well established (GLP-1 receptor agonists slow gastric emptying and act on satiety signalling in the brain) so many people notice their appetite has already changed substantially before they reach 2.4mg. Side effects at 1.7mg are typically similar in character to earlier steps: nausea, loose stools, and fatigue are the most commonly reported, usually settling within the first week or two of that dose. Anyone experiencing symptoms that feel severe or prolonged should contact their prescriber rather than adjusting the schedule themselves. The next step in the schedule beyond maintenance is a separate clinical consideration, and one a prescriber should lead. For context on how private treatment costs are structured at each dose, the Wegovy pricing page sets that out plainly.

Semaglutide after Wegovy: what happens when treatment ends

One of the most clinically significant findings from the semaglutide programme is what happens when people stop. Weight typically returns over the months following discontinuation, which is why ongoing clinical review matters throughout treatment. The post-Wegovy weight regain page covers this honestly, including what the evidence says and why a prescriber-led plan for the period after treatment is worth thinking about from the start. Wegovy is not a short course; it works alongside sustained lifestyle changes, and NICE's recommendation under TA875 reflects that by limiting NHS-funded use to a maximum of two years within a specialist weight management service. Private treatment has no such mandatory cap, but your prescriber will review your progress before every repeat order. If you'd like to understand whether Wegovy is clinically suitable for you, the place to start is a consultation with our prescribers, check your eligibility via the treatment page.